SCHEMBL2008108

SCHEMBL2008108

COc1ccc(S(=O)(=O)N(C)CCN(C)c2nc(Cc3ccccc3C)ns2)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 1/20 0.40
KEAP1 Q14145 5/20 0.39
LMNA P02545 2/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
RECQL P46063 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 2/20 0.39
KDM4E B2RXH2 2/20 0.38
GBA1 P04062 1/20 0.37
ALDH1A1 P00352 1/20 0.36
NFE2L2 Q16236 1/20 0.36
TP53 P04637 1/20 0.36
MMP1 P03956 1/20 0.35
MMP9 P14780 1/20 0.35
MMP13 P45452 1/20 0.35
ADAM17 P78536 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35
PGR P06401 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1021067 0.90 TAS2R14 (0.40) TAS2R14KEAP1LMNATSHRHTT
SCHEMBL1022239 0.90 ALDH1A1 (0.44) KEAP1LMNATSHRHTTRECQL
SCHEMBL1022400 0.87 ALDH1A1 (0.40) TAS2R14KEAP1LMNATSHRHTT
SCHEMBL1020162 0.86 NOS2 (0.40) TAS2R14LMNATSHRHTTRECQL
SCHEMBL2010437 0.86 ALDH1A1 (0.43) KEAP1LMNASMN1; SMN2MAPTALDH1A1
SCHEMBL2007365 0.84 LMNA (0.45) LMNATSHRHTTRECQLSMN1; SMN2
SCHEMBL1020314 0.83 KDM4E (0.39) TAS2R14KEAP1LMNATSHRHTT
SCHEMBL2005838 0.83 MAPT (0.46) LMNATSHRHTTRECQLSMN1; SMN2
SCHEMBL1020526 0.83 BMP1 (0.41) TAS2R14KEAP1LMNASMN1; SMN2MAPT
SCHEMBL1021588 0.82 MMP1 (0.40) TAS2R14KEAP1LMNAALDH1A1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US claimed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US claimed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP TAS2R14 1979/4885KEAP1 60/4885LMNA 1913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.